Lung Cancer
A New Modality for Treating Recurrent Mediastinal Lung Cancer
Intratumoral Alpha-Emitting Radiotherapeutics for Challenging Mediastinal Tumors
Recurrent mediastinal tumors arising from lung cancer are among the most challenging conditions in thoracic oncology. These tumors develop in the central chest, where vital structures such as the heart, major blood vessels, airways, and esophagus are tightly packed. After surgery, chemotherapy, and radiation, cancer can return in the mediastinal lymph nodes, often becoming more aggressive and resistant to further treatment. Because of their proximity to these critical organs, additional surgery or repeat radiation could be unsafe or not feasible, leaving patients with limited treatment options beyond symptom management.
Alpha DaRT offers a potential treatment option for patients with recurrent mediastinal lung cancer. Designed to place alpha-emitting sources directly into the tumor, the therapy aims to deliver intense, short-range radiation to target cancer cells from within, while potentially limiting impact on surrounding tissue. This intratumoral approach has the potential to provide the precision needed in the mediastinum and may be used either alone or in combination with systemic therapies such as immunotherapy to support broader disease control.
Potential Benefits of Alpha DaRT for Lung Cancer
Recurrent mediastinal lung cancer reflects a convergence of two major challenges: the biological aggressiveness of tumors that have survived prior therapy and the anatomical complexity of the region in which they grow. Together, these factors limit the effectiveness of many standard treatments and create a setting in which more targeted, localized approaches may offer meaningful advantages.
Potential benefits of Alpha DaRT include:
Intratumoral delivery of alpha-emitting therapy
directly into mediastinal tumors
Ultra-short-range radiation
designed to focus its effect within the tumor while potentially limiting impact on nearby organs
Applicable to tumors in high-risk central chest locations
where other treatments may be constrained
Potential activity in treatment-resistant and hypoxic tumor regions
Minimally invasive, image-guided placement
compatible with bronchoscopic or percutaneous techniques
Single-procedure treatment
reducing the need for prolonged therapy courses
Can be combined with systemic treatments
including immunotherapy
Designed to support preservation of organ function and quality of life
Delivery of Alpha DaRT to Mediastinal Tumors
In the EBUS-guided approach, performed by an experienced interventional pulmonologist, a bronchoscope equipped with an ultrasound probe is advanced through the airways to visualize the mediastinal tumor in real time and define its size and location. A standard biopsy needle, preloaded with Alpha DaRT sources, is passed through the bronchoscope’s working channel and inserted into the tumor, delivering the sources, enabling controlled placement within the tumor volume.
Frequently Asked Questions about Alpha DaRT for Lung Cancer
Why might someone consider Alpha DaRT as a treatment for lung cancers?
Recurrent mediastinal lung cancers can be particularly difficult to treat because tumors often return after prior surgery, chemotherapy, or radiation. These tumors typically develop in the central chest near critical structures such as the heart, major blood vessels, airways, and esophagus. In many cases, additional surgery or repeat radiation may not be feasible due to safety concerns.
Alpha DaRT is being investigated as a potential localized treatment option for recurrent mediastinal lung tumors. By placing alpha-emitting sources directly inside the tumor, Alpha DaRT is designed to deliver concentrated radiation within the lesion while potentially limiting exposure to surrounding organs. This approach may be particularly relevant for patients with limited treatment options and tumors located in anatomically complex regions.
How is Alpha DaRT delivered in lung tumors?
The Alpha DaRT has been designed to work seamlessly into existing bronchoscopic workflows to minimize may be delivered to mediastinal lung tumors using a non-surgical bronchoscopic approach. Using endobronchial ultrasound (EBUS) imaging techniques, a standard biopsy needle preloaded with Alpha DaRT sources is guided through the bronchoscope and inserted directly into the tumor. The sources are placed in a controlled pattern within the tumor to achieve planned coverage of the target area.
Can Alpha DaRT be combined with other cancer treatments for lung cancer?
Potentially yes. Alpha DaRT is being evaluated both as a standalone treatment and in combination with systemic therapies. In recurrent mediastinal lung cancer, combination approaches may include treatments such as immunotherapy that aim to control disease beyond the treated tumor.
Where can someone find the Alpha DaRT treatment for lung cancer in the U.S.?
Alpha DaRT is not currently available in the U.S. for the treatment of lung cancer. Alpha DaRT is not currently authorized for use or commercial sale outside of the context of an approved clinical trial and there are currently no clinical trials for this indication in the U.S. Follow our Newsroom to receive updates on new clinical trials.